2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomach Neoplasms
57
Carcinoma, Hepatocellular
45
Carcinoma, Non-Small-Cell Lung
23
Small Cell Lung Carcinoma
19
Ovarian Neoplasms
18
Colorectal Neoplasms
18
Breast Neoplasms
17
Sarcoma
14
Neoplasms
14
Triple Negative Breast Neoplasms
13
Nasopharyngeal Carcinoma
11
Lung Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Cholangiocarcinoma
10
Osteosarcoma
9
Esophageal Neoplasms
9
Advanced Gastric Cancer
9
Neoplasm Metastasis
8
Biliary Tract Neoplasms
8
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Recurrence
6
Pancreatic Neoplasms
6
Head and Neck Neoplasms
6
Liver Neoplasms
5
Glioma
5
Thyroid Neoplasms
4
Solid Tumor
4
Melanoma
4
Drug-Related Side Effects and Adverse Reactions
4
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
apatinib
×
Clear all
NCT03407976
2020-07-15
APPEASE
University of Utah
Phase 1
Terminated
5 enrolled